

# DRIVING EXCEPTIONAL CHANGE FOR TUBERCULOSIS BETTER MEDICINES AND DIAGNOSTICS



Every year TB kills around 1.3 million people, many of them living with HIV. More than 3 million new TB cases go undiagnosed annually. For decades there were no new TB tests or treatments. Child-friendly medicines were unheard of and TB drug resistance was rising unchecked.

Recent successes have given a new era of hope. Hope generated by significant increases in improved TB testing. Hope for children through new initiatives to develop better medicines. Hope for those struggling with the most complex drug-resistant forms of the disease through improved testing and efforts to improve access to new simplified and less aggressive treatment regimens.

UNITAID is driving much of this change. Through its deep analysis of opportunities and short-term investments in product markets, it makes better prevention, diagnosis and treatment products more accessible globally and on a long-term basis.

## MORE AFFORDABLE, SIMPLER AND FASTER TESTING


- Through UNITAID's EXPAND-TB project, new multi-drug resistant TB (MDR-TB) diagnostic platforms have been installed in 27 countries that carry 40% of the MDR-TB disease burden, enabling MDR-TB testing for the first time for many, and **detecting over a quarter of all global MDR-TB cases**, including with HIV co-infection (in 2013).
- GeneXpert machines have been installed in 21 countries, providing testing for drug-resistant strains in hours instead of weeks to enable faster initiation of treatment. This was the **largest global scale up** at the time and **signalled to other funders that the latest technology is both viable and essential** even in the lowest resource settings.
- GeneXpert® TB cartridges were too costly for most TB-affected countries until UNITAID, with the Bill and Melinda Gates Foundation, PEPFAR and USAID, negotiated a **global 40% price reduction for 145 countries**. This has enabled all major TB funders including the Global Fund and national programmes to benefit on an indefinite basis. Over **\$50 million has already been saved** in under two years, including for South Africa and Brazil.
- Much of the credit is given to the EXPAND-TB and TB Xpert projects for the 30% increase in MDR-TB case detection in 2013.

## IMPROVING ACCESS TO THE BEST MEDICINES FOR THE MOST VULNERABLE

- UNITAID is accelerating large-scale access to **new world-class regimens for MDR-TB to drive a tenfold decrease in new infections** and help close the treatment gap created by the increase in detection.
- With over half a million new paediatric TB cases a year, securing access to child-friendly medicines is a UNITAID priority. It is investing in the **development of new formulations**, plus has supplied over a **seventh of all existing public sector paediatric medicines** in recent years.
- UNITAID has provided nearly 800,000 first line treatments for the 19 hardest-hit countries.
- UNITAID provides **global access to an emergency stockpile** of MDR-TB medicines, preventing treatment supply interruptions for all countries at risk.
- The market for MDR-TB treatments is small and fragmented with up to 40 different regimens ordered by many different purchasers. UNITAID strives to improve this patchy and unpredictable market through its robust disease, product and market analysis to continually explore new ways for demand forecasting, treatment simplification, production stabilisation and improved purchaser coordination.



*Ernest is on an arduous two-year treatment for MDR-TB. New simplified regimens can cut treatment time to 6-9 months, and make it easier for him to complete his course.*



## Top 10 countries by financial values<sup>1</sup> (US\$) 2007-2013

INDIA	36,786,921
AZERBAIJAN	6,239,411
MYANMAR	5,899,501
KYRGYZSTAN	5,482,167
KENYA	4,289,741
BANGLADESH	3,937,092
LESOTHO	3,628,535
UZBEKISTAN	3,134,395
GEORGIA	2,551,249
NIGERIA	2,412,125

US\$ Cumulative value delivered

## Grantees



## Results<sup>2</sup> by project (Includes all project countries, 2007-2013\*)

PROJECT	DURATION	DESCRIPTION	RESULTS
Paediatric TB (STOP-TB/GDF)	12/01/2007 - 31/12/2013	# of paediatric TB (prophylaxis) patient treatments delivered	768,009
		# of paediatric TB (curative) patient treatments delivered	523,641
Expand MDR TB Diagnostics (STOP-TB, WHO, FIND)	10/12/2008 - 31/12/2014	# of MDR-TB cases detected	71,824
First Line TB (STOP-TB/GDF)	11/09/2007 - 31/12/2011	# of first-line TB treatments delivered	785,080
MDR TB Scale Up (STOP-TB/GDF)	25/07/2007 - 31/12/2013	# of MDR-TB patient treatments delivered <sup>2</sup>	16,309
MDR TB Strategic Rotating Stockpile (STOP-TB/GDF)	20/11/2008 - 30/06/2015	# of MDR-TB treatments available in the SRS	5,800
Support to Global Fund Round 6 (GFATM)	21/12/2007 - 31/12/2011	# of MDR-TB patient treatments delivered <sup>2</sup>	3,434
TB Xpert (WHO)	28/01/2013 - 31/12/2015	# of incident TB patients detected	7,647
		# of incident HIV-positive TB patients detected	992
		# of incident rifampicin-resistant TB patients detected	1,791
		# of Xpert MTB/RIF tests performed	57,018
		# of GeneXpert instrument modules procured	844
		# of Xpert MTB/RIF cartridges procured/delivered	234,760
STEP Paediatric TB (TB Alliance)	22/07/2013 - 22/07/2016	# of signed agreements/MOUs for formulation devt with manufa.	2
		# of market studies conducted	6
Prequalification of Medicines (WHO)	14/12/2006 - 31/12/2016	Number of UNITAID priority medicines prequalified (TB)	58

### Data as of 31 December 2013.

Visit <http://www.unitaid.eu/en/what/tb>

<sup>1</sup> Value (US\$) of products provided to countries.

<sup>2</sup> Each treatment provided represents treatment for an 18 to 24 month period. Variations in patient treatment costs across countries are due to the different treatment regimens adopted by each country.